{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:35:35Z","timestamp":1794501335545,"version":"4.9.1"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Duchenne muscular dystrophy (DMD) is caused by pathogenic sequence variants occurring in the <jats:italic>DMD<\/jats:italic> gene which lead to the loss of the dystrophin protein, a molecular \u2018shock absorber\u2019 that protects muscle from contraction-induced injury. The large size of the dystrophin open reading frame precludes delivery of the full-length protein using a single adeno-associated virus (AAV) vector, which led to the development of internally-deleted dystrophin minigenes encoding partially-functional dystrophin. Indeed, five such microdystrophin therapies have been assessed in various clinical programmes. In 2023, Elevidys (Sarepta Therapeutics) received accelerated approval based on levels of dystrophin as a surrogate biomarker. In 2024, it received full approval despite unclear efficacy (i.e. not meeting primary or secondary outcomes in a phase 3 trial). Additionally, in 2025, two DMD individuals treated with Elevidys died after acute liver failure. A separate microdystrophin therapy, PF-06939926 (Pfizer) was discontinued for both efficacy and safety reasons (including the deaths of two clinical trial participants). Solid Biosciences, Genethon, REGENXBIO, and Insmed continue to develop microdystrophin therapies differing in transgene structure, promoter sequences, and AAV serotype. Here we describe recent progress in AAV-microdystrophin therapeutics development, and discuss the challenges facing such approaches, including pre-existing anti-capsid immunity, anti-transgene immunity, the unknown functionality of microdystrophin transgenes, transduction of muscle stem cells, and long-term transgene persistence.<\/jats:p>","DOI":"10.1038\/s41434-025-00561-6","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:50:36Z","timestamp":1755265836000},"page":"447-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects"],"prefix":"10.1038","volume":"32","author":[{"given":"Katarzyna","family":"Chwalenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi-Yun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Friedrichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioulia","family":"Vorobieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-6011","authenticated-orcid":false,"given":"Matthew J. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-7631","authenticated-orcid":false,"given":"Thomas C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, B\u00f6nnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394:2025\u201338.","journal-title":"Lancet"},{"key":"561_CR2","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168\u201384.","journal-title":"Molecules"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 1993;90:3710\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2119\/molmed.2011.00049","volume":"17","author":"S Consalvi","year":"2011","unstructured":"Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol Med. 2011;17:457\u201365.","journal-title":"Mol Med"},{"key":"561_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01657-z","volume":"11","author":"N Cardone","year":"2023","unstructured":"Cardone N, Taglietti V, Baratto S, Kefi K, Periou B, Gitiaux C, et al. Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells. Acta Neuropathol Commun. 2023;11:167.","journal-title":"Acta Neuropathol Commun"},{"key":"561_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00234-1","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Prim. 2021;7:1\u201319.","journal-title":"Nat Rev Dis Prim"},{"key":"561_CR7","doi-asserted-by":"publisher","first-page":"e006340","DOI":"10.1161\/JAHA.117.006340","volume":"6","author":"D Cheeran","year":"2017","unstructured":"Cheeran D, Khan S, Khera R, Bhatt A, Garg S, Grodin JL, et al. Predictors of Death in adults with duchenne muscular dystrophy-associated cardiomyopathy. J Am Heart Assoc. 2017;6:e006340.","journal-title":"J Am Heart Assoc"},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ng0295-184","volume":"9","author":"CN Tennyson","year":"1995","unstructured":"Tennyson CN, Klamut HJ, Worton RG. The human dystrophin gene requires 16\u2009hours to be transcribed and is cotranscriptionally spliced. Nat Genet. 1995;9:184\u201390.","journal-title":"Nat Genet"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nsmb.1666","volume":"16","author":"J Singh","year":"2009","unstructured":"Singh J, Padgett RA. Rates of in situ transcription and splicing in large human genes. Nat Struct Mol Biol. 2009;16:1128\u201333.","journal-title":"Nat Struct Mol Biol"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00439-017-1820-9","volume":"136","author":"S Tuffery-Giraud","year":"2017","unstructured":"Tuffery-Giraud S, Miro J, Koenig M, Claustres M. Normal and altered pre-mRNA processing in the DMD gene. Hum Genet. 2017;136:1155\u201372.","journal-title":"Hum Genet"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1399-0004.2009.01173.x","volume":"75","author":"ATJM Helderman-van den Enden","year":"2009","unstructured":"Helderman-van den Enden ATJM, de Jong R, den Dunnen JT, Houwing-Duistermaat JJ, Kneppers ALJ, Ginjaar HB, et al. Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy. Clin Genet. 2009;75:465\u201372.","journal-title":"Clin Genet"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731\u201340.","journal-title":"Lancet Neurol"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1086\/341942","volume":"71","author":"S White","year":"2002","unstructured":"White S, Kalf M, Liu Q, Villerius M, Engelsma D, Kriek M, et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet. 2002;71:365\u201374.","journal-title":"Am J Hum Genet"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N, Motoki H, Miyazaki D, Nishizawa H, et al. Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet. 2016;61:663\u20137.","journal-title":"J Hum Genet"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","volume":"82","author":"DJ Blake","year":"2002","unstructured":"Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291\u2013329.","journal-title":"Physiol Rev"},{"key":"561_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2\u2009+\u2009, Reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253\u2013305.","journal-title":"Physiol Rev"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"12140","DOI":"10.1021\/acsnano.8b05721","volume":"12","author":"S Le","year":"2018","unstructured":"Le S, Yu M, Hovan L, Zhao Z, Ervasti J, Yan J. Dystrophin as a molecular shock absorber. ACS Nano. 2018;12:12140\u20138.","journal-title":"ACS Nano"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ng0493-283","volume":"3","author":"AH Ahn","year":"1993","unstructured":"Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet. 1993;3:283\u201391.","journal-title":"Nat Genet"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"28419","DOI":"10.1074\/jbc.273.43.28419","volume":"273","author":"KJ Amann","year":"1998","unstructured":"Amann KJ, Renley BA, Ervasti JM. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J Biol Chem. 1998;273:28419\u201323.","journal-title":"J Biol Chem"},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"101730","DOI":"10.1016\/j.redox.2020.101730","volume":"37","author":"DM Nelson","year":"2020","unstructured":"Nelson DM, Fasbender EK, Jakubiak MC, Lindsay A, Lowe DA, Ervasti JMRapid. Redox-mediated mechanical susceptibility of the cortical microtubule lattice in skeletal muscle. Redox Biol. 2020;37:101730.","journal-title":"Redox Biol"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1083\/jcb.200905048","volume":"186","author":"KW Prins","year":"2009","unstructured":"Prins KW, Humston JL, Mehta A, Tate V, Ralston E, Ervasti JM. Dystrophin is a microtubule-associated protein. J Cell Biol. 2009;186:363\u20139.","journal-title":"J Cell Biol"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","volume":"119","author":"Y Lai","year":"2009","unstructured":"Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119:624\u201335.","journal-title":"J Clin Invest"},{"key":"561_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1073\/pnas.1211431109","volume":"110","author":"Y Lai","year":"2013","unstructured":"Lai Y, Zhao J, Yue Y, Duan D. \u03b12 and \u03b13 helices of dystrophin R16 and R17 frame a microdomain in the \u03b11 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci USA. 2013;110:525\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR24","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1016\/S0021-9258(19)39599-7","volume":"265","author":"M Koenig","year":"1990","unstructured":"Koenig M, Kunkel LM. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem. 1990;265:4560\u20136.","journal-title":"J Biol Chem"},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"27305","DOI":"10.1074\/jbc.270.45.27305","volume":"270","author":"D Jung","year":"1995","unstructured":"Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem. 1995;270:27305\u201310.","journal-title":"J Biol Chem"},{"key":"561_CR26","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1073\/pnas.94.23.12413","volume":"94","author":"HM Sadoulet-Puccio","year":"1997","unstructured":"Sadoulet-Puccio HM, Rajala M, Kunkel LM. Dystrobrevin and dystrophin: an interaction through coiled-coil\u2009motifs. Proc Natl Acad Sci. 1997;94:12413\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"561_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.128.3.373","volume":"128","author":"A Suzuki","year":"1995","unstructured":"Suzuki A, Yoshida M, Ozawa E. Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J Cell Biol. 1995;128:373\u201381.","journal-title":"J Cell Biol"},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/jcb.122.4.809","volume":"122","author":"JM Ervasti","year":"1993","unstructured":"Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993;122:809\u201323.","journal-title":"J Cell Biol"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/355696a0","volume":"355","author":"O Ibraghimov-Beskrovnaya","year":"1992","unstructured":"Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature. 1992;355:696\u2013702.","journal-title":"Nature"},{"key":"561_CR30","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1093\/hmg\/ddw210","volume":"25","author":"J Zhao","year":"2016","unstructured":"Zhao J, Kodippili K, Yue Y, Hakim CH, Wasala L, Pan X, et al. Dystrophin contains multiple independent membrane-binding domains. Hum Mol Genet. 2016;25:3647\u201353.","journal-title":"Hum Mol Genet"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/brainsci5030275","volume":"5","author":"B Nichols","year":"2015","unstructured":"Nichols B, Takeda S, Yokota T. Nonmechanical roles of dystrophin and associated proteins in exercise, neuromuscular junctions, and brains. Brain Sci. 2015;5:275\u201398.","journal-title":"Brain Sci"},{"key":"561_CR32","doi-asserted-by":"publisher","first-page":"13663","DOI":"10.1073\/pnas.1512991112","volume":"112","author":"JF Garbincius","year":"2015","unstructured":"Garbincius JF, Michele DE. Dystrophin-glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling. Proc Natl Acad Sci USA. 2015;112:13663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.medj.2023.02.005","volume":"4","author":"S Gorokhova","year":"2023","unstructured":"Gorokhova S, Schessl J, Zou Y, Yang ML, Heydemann PT, Sufit RL, et al. Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin. Med. 2023;4:245\u2013251.e3.","journal-title":"Med"},{"key":"561_CR34","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Squire SE, Edwards B, Chen H, Burns DT, Shah N, et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015;24:4212\u201324.","journal-title":"Hum Mol Genet"},{"key":"561_CR35","first-page":"209","volume":"24","author":"RC Hirst","year":"2005","unstructured":"Hirst RC, McCullagh KJA, Davies KE. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol. 2005;24:209\u201316.","journal-title":"Acta Myol"},{"key":"561_CR36","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1093\/hmg\/ddv381","volume":"24","author":"TC Roberts","year":"2015","unstructured":"Roberts TC, Johansson HJ, McClorey G, Godfrey C, Blomberg KEM, Coursindel T, et al. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet. 2015;24:6756\u201368.","journal-title":"Hum Mol Genet"},{"key":"561_CR37","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1074\/mcp.RA120.002345","volume":"19","author":"TLE van Westering","year":"2020","unstructured":"van Westering TLE, Johansson HJ, Hanson B, Coenen-Stass AML, Lomonosova Y, Tanihata J, et al. Mutation-independent proteomic signatures of pathological progression in murine models of Duchenne muscular dystrophy. Mol Cell Proteom. 2020;19:2047\u201367.","journal-title":"Mol Cell Proteom"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","volume":"66","author":"JM Ervasti","year":"1991","unstructured":"Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991;66:1121\u201331.","journal-title":"Cell"},{"key":"561_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery AE. The muscular dystrophies. Lancet. 2002;359:687\u201395.","journal-title":"Lancet"},{"key":"561_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90\u201395.","journal-title":"Genomics"},{"key":"561_CR41","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","volume":"24","author":"A Nicolas","year":"2015","unstructured":"Nicolas A, Ragu\u00e9n\u00e8s-Nicol C, Ben Yaou R, Ameziane-Le Hir S, Ch\u00e9ron A, Vi\u00e9 V, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet. 2015;24:1267\u201379.","journal-title":"Hum Mol Genet"},{"key":"561_CR42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.24880","volume":"53","author":"J Chung","year":"2016","unstructured":"Chung J, Smith AL, Hughes SC, Niizawa G, Abdel-Hamid HZ, Naylor EW, et al. Twenty-year follow-up of newborn screening for patients with muscular dystrophy. Muscle Nerve. 2016;53:570\u20138.","journal-title":"Muscle Nerve"},{"key":"561_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180\u20132.","journal-title":"Nature"},{"key":"561_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mus.21193","volume":"39","author":"V Ferreiro","year":"2009","unstructured":"Ferreiro V, Giliberto F, Mu\u00f1iz GMN, Francipane L, Marzese DM, Mampel A, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve. 2009;39:239\u201343.","journal-title":"Muscle Nerve"},{"key":"561_CR45","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","volume":"85","author":"JC Bergen","year":"2014","unstructured":"Bergen JC van den, Wokke BH, Janson AA, Duinen SG van, Hulsker MA, Ginjaar HB, et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry. 2014;85:747\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"561_CR46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5435\/00124635-200203000-00009","volume":"10","author":"M Sussman","year":"2002","unstructured":"Sussman M. Duchenne muscular dystrophy. J Am Acad Orthop Surg. 2002;10:138\u201351.","journal-title":"J Am Acad Orthop Surg"},{"key":"561_CR47","first-page":"54","volume":"49","author":"AH Beggs","year":"1991","unstructured":"Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 1991;49:54\u201367.","journal-title":"Am J Hum Genet"},{"key":"561_CR48","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain. 2011;134:3547\u201359.","journal-title":"Brain"},{"key":"561_CR49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmg.28.12.860","volume":"28","author":"DR Love","year":"1991","unstructured":"Love DR, Flint TJ, Genet SA, Middleton-Price HR, Davies KE. Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy. J Med Genet. 1991;28:860\u20134.","journal-title":"J Med Genet"},{"key":"561_CR50","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D, Systemic AAV. Micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26:2337\u201356.","journal-title":"Mol Ther"},{"key":"561_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/364725a0","volume":"364","author":"GA Cox","year":"1993","unstructured":"Cox GA, Cole NM, Matsumura K, Phelps SF, Hauschka SD, Campbell KP, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 1993;364:725\u20139.","journal-title":"Nature"},{"key":"561_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","volume":"32","author":"RA Potter","year":"2021","unstructured":"Potter RA, Griffin DA, Heller KN, Peterson EL, Clark EK, Mendell JR, et al. Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy. Hum Gene Ther. 2021;32:375\u201389.","journal-title":"Hum Gene Ther"},{"key":"561_CR53","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","volume":"24","author":"Y Yue","year":"2015","unstructured":"Yue Y, Pan X, Hakim CH, Kodippili K, Zhang K, Shin J-H, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet. 2015;24:5880\u201390.","journal-title":"Hum Mol Genet"},{"key":"561_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.","journal-title":"Nat Commun"},{"key":"561_CR55","doi-asserted-by":"publisher","first-page":"eabo1815","DOI":"10.1126\/scitranslmed.abo1815","volume":"15","author":"SM Birch","year":"2023","unstructured":"Birch SM, Lawlor MW, Conlon TJ, Guo L-J, Crudele JM, Hawkins EC, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15:eabo1815.","journal-title":"Sci Transl Med"},{"key":"561_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","volume":"6","author":"CH Hakim","year":"2017","unstructured":"Hakim CH, Wasala NB, Pan X, Kodippili K, Yue Y, Zhang K, et al. A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA\/2J-mdx model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev. 2017;6:216\u201330.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR57","doi-asserted-by":"crossref","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov 2023;22:917\u201334.","DOI":"10.1038\/s41573-023-00775-6"},{"key":"561_CR58","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","volume":"18","author":"B Hanson","year":"2021","unstructured":"Hanson B, Wood MJA, Roberts TC. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. RNA Biol. 2021;18:1048\u201362.","journal-title":"RNA Biol"},{"key":"561_CR59","doi-asserted-by":"publisher","unstructured":"Chwalenia K, Wood MJA, Roberts TC. Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy. J Muscle Res Cell Motil 2025. https:\/\/doi.org\/10.1007\/s10974-024-09688-2.","DOI":"10.1007\/s10974-024-09688-2"},{"key":"561_CR60","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83:1323\u20139.","journal-title":"Drugs"},{"key":"561_CR61","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"561_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372.","journal-title":"Nat Rev Genet"},{"key":"561_CR63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14:316\u201327.","journal-title":"Mol Ther"},{"key":"561_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1566523034578285","volume":"3","author":"D Grimm","year":"2003","unstructured":"Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther. 2003;3:281\u2013304.","journal-title":"Curr Gene Ther"},{"key":"561_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00439-006-0165-6","volume":"119","author":"KH Warrington","year":"2006","unstructured":"Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 2006;119:571\u2013603.","journal-title":"Hum Genet"},{"key":"561_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2174\/1566523034578131","volume":"3","author":"L Tenenbaum","year":"2003","unstructured":"Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003;3:545\u201365.","journal-title":"Curr Gene Ther"},{"key":"561_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/15665232113136660007","volume":"13","author":"DJ Dismuke","year":"2013","unstructured":"Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther. 2013;13:434\u201352.","journal-title":"Curr Gene Ther"},{"key":"561_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF02253246","volume":"7","author":"J Tal","year":"2000","unstructured":"Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci. 2000;7:279\u201391.","journal-title":"J Biomed Sci"},{"key":"561_CR69","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1128\/JVI.78.1.441-453.2004","volume":"78","author":"TH Stracker","year":"2004","unstructured":"Stracker TH, Cassell GD, Ward P, Loo Y-M, van Breukelen B, Carrington-Lawrence SD, et al. The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol. 2004;78:441\u201353.","journal-title":"J Virol"},{"key":"561_CR70","doi-asserted-by":"publisher","first-page":"12381","DOI":"10.1073\/pnas.182430299","volume":"99","author":"NJ Philpott","year":"2002","unstructured":"Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E. A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci USA. 2002;99:12381\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR71","doi-asserted-by":"publisher","first-page":"e1000985","DOI":"10.1371\/journal.ppat.1000985","volume":"6","author":"D H\u00fcser","year":"2010","unstructured":"H\u00fcser D, Gogol-D\u00f6ring A, Lutter T, Weger S, Winter K, Hammer E-M, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog. 2010;6:e1000985.","journal-title":"PLoS Pathog"},{"key":"561_CR72","doi-asserted-by":"publisher","first-page":"6612","DOI":"10.1128\/JVI.00356-16","volume":"90","author":"M Bardelli","year":"2016","unstructured":"Bardelli M, Z\u00e1rate-P\u00e9rez F, Ag\u00fandez L, Linden RM, Escalante CR, Henckaerts E. Identification of a functionally relevant adeno-associated virus Rep68 oligomeric interface. J Virol. 2016;90:6612\u201324.","journal-title":"J Virol"},{"key":"561_CR73","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1093\/emboj\/20.12.3282","volume":"20","author":"JA King","year":"2001","unstructured":"King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 2001;20:3282\u201391.","journal-title":"EMBO J"},{"key":"561_CR74","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1089\/hum.1994.5.7-793","volume":"5","author":"RM Kotin","year":"1994","unstructured":"Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. 1994;5:793\u2013801.","journal-title":"Hum Gene Ther"},{"key":"561_CR75","doi-asserted-by":"publisher","first-page":"15047","DOI":"10.1038\/mtm.2015.47","volume":"2","author":"JM Kelich","year":"2015","unstructured":"Kelich JM, Ma J, Dong B, Wang Q, Chin M, Magura CM, et al. Super-resolution imaging of nuclear import of adeno-associated virus in live cells. Mol Ther Methods Clin Dev. 2015;2:15047.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR76","first-page":"167","volume":"13","author":"SL Junod","year":"2021","unstructured":"Junod SL, Saredy J, Yang W. Nuclear import of adeno-associated. Viruses Image High-Speed Single-Mol Microsc Viruses. 2021;13:167.","journal-title":"Viruses Image High-Speed Single-Mol Microsc Viruses"},{"key":"561_CR77","doi-asserted-by":"publisher","first-page":"9163","DOI":"10.1128\/JVI.00282-12","volume":"86","author":"R Popa-Wagner","year":"2012","unstructured":"Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M, Florin L, et al. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol. 2012;86:9163\u201374.","journal-title":"J Virol"},{"key":"561_CR78","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1128\/JVI.07232-11","volume":"86","author":"MA DiMattia","year":"2012","unstructured":"DiMattia MA, Nam H-J, Van Vliet K, Mitchell M, Bennett A, Gurda BL, et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol. 2012;86:6947\u201358.","journal-title":"J Virol"},{"key":"561_CR79","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.aaw2900","volume":"366","author":"PJ Ogden","year":"2019","unstructured":"Ogden PJ, Kelsic ED, Sinai S, Church GM, Comprehensive AAV. Capsid fitness landscape reveals a viral gene and enables machine-guided design. Science. 2019;366:1139\u201343.","journal-title":"Science"},{"key":"561_CR80","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1073\/pnas.1001673107","volume":"107","author":"F Sonntag","year":"2010","unstructured":"Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci. 2010;107:10220\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"561_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2015.03.007","volume":"482","author":"M Cao","year":"2015","unstructured":"Cao M, Chiriva-Internati M, Hermonat PL. AAV2 X increases AAV6 rep\/cap-driven rAAV production. Virology. 2015;482:84\u201388.","journal-title":"Virology"},{"key":"561_CR82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chom.2011.10.014","volume":"10","author":"M Nonnenmacher","year":"2011","unstructured":"Nonnenmacher M, Weber T. Adeno-associated virus 2 infection requires endocytosis through the CLIC\/GEEC pathway. Cell Host Microbe. 2011;10:563\u201376.","journal-title":"Cell Host Microbe"},{"key":"561_CR83","doi-asserted-by":"publisher","first-page":"10371","DOI":"10.1128\/JVI.73.12.10371-10376.1999","volume":"73","author":"D Duan","year":"1999","unstructured":"Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol. 1999;73:10371\u20136.","journal-title":"J Virol"},{"key":"561_CR84","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, et al. An essential receptor for adeno-associated virus infection. Nature. 2016;530:108\u201312.","journal-title":"Nature"},{"key":"561_CR85","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","volume":"20","author":"A Asokan","year":"2012","unstructured":"Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20:699\u2013708.","journal-title":"Mol Ther"},{"key":"561_CR86","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/JVI.00649-08","volume":"82","author":"M Penaud-Budloo","year":"2008","unstructured":"Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Ch\u00e9rel Y, Chenuaud P, et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol. 2008;82:7875\u201385.","journal-title":"J Virol"},{"key":"561_CR87","doi-asserted-by":"publisher","first-page":"14793","DOI":"10.1128\/JVI.79.23.14793-14803.2005","volume":"79","author":"BC Schnepp","year":"2005","unstructured":"Schnepp BC, Jensen RL, Chen C-L, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005;79:14793.","journal-title":"J Virol"},{"key":"561_CR88","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","volume":"72","author":"D Duan","year":"1998","unstructured":"Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72:8568\u201377.","journal-title":"J Virol"},{"key":"561_CR89","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.gt.3302233","volume":"11","author":"TR Flotte","year":"2004","unstructured":"Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004;11:805\u201310.","journal-title":"Gene Ther"},{"key":"561_CR90","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1073\/pnas.080079397","volume":"97","author":"N Dutheil","year":"2000","unstructured":"Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA. 2000;97:4862\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR91","first-page":"748","volume":"3","author":"WG Kearns","year":"1996","unstructured":"Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, Egan M, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 1996;3:748\u201355.","journal-title":"Gene Ther"},{"key":"561_CR92","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1128\/jvi.68.9.5656-5666.1994","volume":"68","author":"G Podsakoff","year":"1994","unstructured":"Podsakoff G, Wong KK, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol. 1994;68:5656\u201366.","journal-title":"J Virol"},{"key":"561_CR93","doi-asserted-by":"publisher","first-page":"8915","DOI":"10.1073\/pnas.91.19.8915","volume":"91","author":"DW Russell","year":"1994","unstructured":"Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA. 1994;91:8915\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19230-w","volume":"11","author":"J Weinmann","year":"2020","unstructured":"Weinmann J, Weis S, Sippel J, Tulalamba W, Remes A, El Andari J, et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun. 2020;11:5432.","journal-title":"Nat Commun"},{"key":"561_CR95","first-page":"Unit 14D.3","volume":"Chapter 14","author":"AM Gruntman","year":"2013","unstructured":"Gruntman AM, Bish LT, Mueller C, Sweeney HL, Flotte TR, Gao G. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol. 2013;Chapter 14:Unit 14D.3.","journal-title":"Curr Protoc Microbiol"},{"key":"561_CR96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-61779-370-7_5","volume":"807","author":"C Qiao","year":"2011","unstructured":"Qiao C, Koo T, Li J, Xiao X, Dickson JG. Gene therapy in skeletal muscle mediated by adeno-associated virus vectors. Methods Mol Biol. 2011;807:119\u201340.","journal-title":"Methods Mol Biol"},{"key":"561_CR97","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10:828\u201334.","journal-title":"Nat Med"},{"key":"561_CR98","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","volume":"72","author":"C Summerford","year":"1998","unstructured":"Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72:1438\u201345.","journal-title":"J Virol"},{"key":"561_CR99","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18:80\u201386.","journal-title":"Mol Ther"},{"key":"561_CR100","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","volume":"12","author":"H B\u00fcning","year":"2019","unstructured":"B\u00fcning H, Srivastava A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev. 2019;12:248\u201365.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR101","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78:6381\u20138.","journal-title":"J Virol"},{"key":"561_CR102","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine LG, Rodino-Klapac LR, Shao G, Xu R, Bremer WG, Camboni M, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol Ther. 2014;22:713\u201324.","journal-title":"Mol Ther"},{"key":"561_CR103","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919\u20134938.e22.","journal-title":"Cell"},{"key":"561_CR104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther. 2024;9:1\u201333.","journal-title":"Sig Transduct Target Ther"},{"key":"561_CR105","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/mt.2012.194","volume":"20","author":"S Yl\u00e4-Herttuala","year":"2012","unstructured":"Yl\u00e4-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20:1831\u20132.","journal-title":"Mol Ther"},{"key":"561_CR106","first-page":"1427","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Eladocagene exuparvovec: first approval. Drugs. 2022;82:1427\u201332.","journal-title":"Drugs"},{"key":"561_CR107","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021;29:464\u201388.","journal-title":"Mol Ther"},{"key":"561_CR108","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nbt0617-491","volume":"35","author":"M Senior","year":"2017","unstructured":"Senior M. After Glybera\u2019s withdrawal, what\u2019s next for gene therapy? Nat Biotechnol. 2017;35:491\u20132.","journal-title":"Nat Biotechnol"},{"key":"561_CR109","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15:320\u20139.","journal-title":"Mol Ther"},{"key":"561_CR110","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1006\/jmcc.1996.0112","volume":"28","author":"JD Molkentin","year":"1996","unstructured":"Molkentin JD, Jobe SM, Markham BE. Alpha-myosin heavy chain gene regulation: delineation and characterization of the cardiac muscle-specific enhancer and muscle-specific promoter. J Mol Cell Cardiol. 1996;28:1211\u201325.","journal-title":"J Mol Cell Cardiol"},{"key":"561_CR111","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1089\/hum.2016.141","volume":"28","author":"DA Zygmunt","year":"2017","unstructured":"Zygmunt DA, Crowe KE, Flanigan KM, Martin PT. Comparison of Serum rAAV serotype-specific antibodies in patients with duchenne muscular dystrophy, becker muscular dystrophy, inclusion body myositis, or GNE Myopathy. Hum Gene Ther. 2017;28:737\u201346.","journal-title":"Hum Gene Ther"},{"key":"561_CR112","unstructured":"Commissioner O of the. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy. FDA. 2024.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy (accessed 15 Aug 2024)."},{"key":"561_CR113","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/hum.2022.190","volume":"34","author":"JS Chamberlain","year":"2023","unstructured":"Chamberlain JS, Robb M, Braun S, Brown KJ, Danos O, Ganot A, et al. Microdystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Hum Gene Ther. 2023;34:404\u201315.","journal-title":"Hum Gene Ther"},{"key":"561_CR114","unstructured":"Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above | Sarepta Therapeutics, Inc. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys (accessed 15 Aug 2024)."},{"key":"561_CR115","unstructured":"Commissioner O of the. FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy. FDA. 2024.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy (accessed 12 May 2025)."},{"key":"561_CR116","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77:1122\u201331.","journal-title":"JAMA Neurol"},{"key":"561_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial. Muscle Nerve. 2024;69:93\u201398.","journal-title":"Muscle Nerve"},{"key":"561_CR118","doi-asserted-by":"publisher","unstructured":"Mendell JR, Shieh PB, McDonald CM, Sahenk Z, Lehman KJ, Lowes LP, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 2023;11. https:\/\/doi.org\/10.3389\/fcell.2023.1167762.","DOI":"10.3389\/fcell.2023.1167762"},{"key":"561_CR119","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, Lehman KJ, Goedeker NL, Mason S, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94:955\u201368.","journal-title":"Ann Neurol"},{"key":"561_CR120","doi-asserted-by":"crossref","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med 2024;1\u201310.","DOI":"10.1038\/s41591-024-03304-z"},{"key":"561_CR121","unstructured":"Marks, Peter. CENTER DIRECTOR DECISIONAL MEMO BLA 125781\/AMENDMENT 34. https:\/\/www.fda.gov\/media\/179485\/download."},{"key":"561_CR122","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JND-210646","volume":"8","author":"T Duong","year":"2021","unstructured":"Duong T, Canbek J, Birkmeier M, Nelson L, Siener C, Fernandez-Fernandez A, et al. The minimal clinical important difference (MCID) in annual rate of change of timed function tests in boys with DMD. J Neuromuscul Dis. 2021;8:939\u201348.","journal-title":"J Neuromuscul Dis"},{"key":"561_CR123","unstructured":"Community Letter: ELEVIDYS Safety Update | Sarepta Therapeutics. https:\/\/www.sarepta.com\/community-letter-elevidys-safety-update (accessed 12 May 2025)."},{"key":"561_CR124","unstructured":"Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne | Sarepta Therapeutics, Inc. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-provides-safety-update-elevidys-and-initiates-steps (accessed 8 Jul 2025)."},{"key":"561_CR125","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.nmd.2022.12.007","volume":"33","author":"JF Boehler","year":"2023","unstructured":"Boehler JF, Brown KJ, Beatka M, Gonzalez JP, Donisa Dreghici R, Soustek-Kramer M, et al. Clinical potential of microdystrophin as a surrogate endpoint. Neuromuscul Disord. 2023;33:40\u201349.","journal-title":"Neuromuscul Disord"},{"key":"561_CR126","unstructured":"Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD) | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd (accessed 28 Jan2025)."},{"key":"561_CR127","unstructured":"Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-receives-fda-fast-track-designation-duchenne (accessed 2 Sep2024)."},{"key":"561_CR128","unstructured":"One year data from ambulatory boys in a phase 1b, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD). MDA Clinical & Scientific Conference 2025. https:\/\/www.mdaconference.org\/abstract-library\/one-year-data-from-ambulatory-boys-in-a-phase-1b-open-label-study-of-fordadistrogene-movaparvovec-pf-06939926-for-duchenne-muscular-dystrophy-dmd\/ (accessed 18 Feb 2025)."},{"key":"561_CR129","unstructured":"PF-06939926 Continues to Show Safety and Efficacy in Duchenne Muscular Dystrophy. Neurology live. 2021. https:\/\/www.neurologylive.com\/view\/pf-06939926-safe-efficacious-dmd (accessed 18 Feb 2025)."},{"key":"561_CR130","unstructured":"Pfizer - CIFFREO|DMD Hub. https:\/\/dmdhub.org\/trials\/pfizer-ciffreo\/ (accessed 18 Feb 2025)."},{"key":"561_CR131","unstructured":"Parent Project Muscular Dystrophy. Pfizer Announces Amendment to Ongoing Gene Therapy Phase III Trial. Parent Project Muscular Dystrophy. 2021. https:\/\/www.parentprojectmd.org\/pfizer-announces-amendment-to-ongoing-gene-therapy-phase-iii-trial\/ (accessed 18 Feb 2025)."},{"key":"561_CR132","doi-asserted-by":"publisher","unstructured":"B\u00f6nnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med 2023. https:\/\/doi.org\/10.1056\/NEJMc2212912.","DOI":"10.1056\/NEJMc2212912"},{"key":"561_CR133","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/hum.2022.180","volume":"34","author":"LP Wasala","year":"2023","unstructured":"Wasala LP, Watkins TB, Wasala NB, Burke MJ, Yue Y, Lai Y, et al. The implication of hinge 1 and hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy. Hum Gene Ther. 2023;34:459\u201370.","journal-title":"Hum Gene Ther"},{"key":"561_CR134","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. After Patient Death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum Gene Ther. 2022;33:111\u20135.","journal-title":"Hum Gene Ther"},{"key":"561_CR135","unstructured":"Parent Project Muscular Dystrophy. Update on Pfizer\u2019s Phase 2 Gene Therapy Trial for Duchenne. Parent Project Muscular Dystrophy. 2024. https:\/\/www.parentprojectmd.org\/update-on-pfizers-phase-2-gene-therapy-trial-for-duchenne\/ (accessed 18 Feb 2025)."},{"key":"561_CR136","unstructured":"Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-phase-3-study-investigational-gene (accessed 18 Feb 2025)."},{"key":"561_CR137","unstructured":"Dystrophy PPM. Pfizer Discontinues Development of Investigational Mini-Dystrophin Gene Therapy. Parent Project Muscular Dystrophy. 2024. https:\/\/www.parentprojectmd.org\/pfizer-discontinues-development-of-investigational-mini-dystrophin-gene-therapy\/ (accessed 18 Feb 2025)."},{"key":"561_CR138","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/brain\/awg017","volume":"126","author":"H Wiendl","year":"2003","unstructured":"Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, et al. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain. 2003;126:176\u201385.","journal-title":"Brain"},{"key":"561_CR139","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/1531-8249(200010)48:4<679::AID-ANA19>3.0.CO;2-V","volume":"48","author":"H Wiendl","year":"2000","unstructured":"Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol. 2000;48:679\u201384.","journal-title":"Ann Neurol"},{"key":"561_CR140","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0165-5728(03)00093-6","volume":"138","author":"H Wiendl","year":"2003","unstructured":"Wiendl H, Lautwein A, Mitsd\u00f6rffer M, Krause S, Erfurth S, Wienhold W, et al. Antigen processing and presentation in human muscle: Cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol. 2003;138:132\u201343.","journal-title":"J Neuroimmunol"},{"key":"561_CR141","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","volume":"9","author":"K Yuasa","year":"2002","unstructured":"Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 2002;9:1576\u201388.","journal-title":"Gene Ther"},{"key":"561_CR142","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hum.2023.056","volume":"34","author":"SRP Kumar","year":"2023","unstructured":"Kumar SRP, Duan D, Herzog RW. Immune responses to muscle-directed adeno-associated viral gene transfer in clinical studies. Hum Gene Ther. 2023;34:365\u201371.","journal-title":"Hum Gene Ther"},{"key":"561_CR143","doi-asserted-by":"publisher","first-page":"814174","DOI":"10.3389\/fneur.2021.814174","volume":"12","author":"A Manini","year":"2021","unstructured":"Manini A, Abati E, Nuredini A, Corti S, Comi GP. Adeno-Associated Virus (AAV)-Mediated gene therapy for Duchenne muscular dystrophy: the issue of transgene persistence. Front Neurol. 2021;12:814174.","journal-title":"Front Neurol"},{"key":"561_CR144","doi-asserted-by":"publisher","first-page":"11040","DOI":"10.1128\/JVI.01056-06","volume":"80","author":"F Sonntag","year":"2006","unstructured":"Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsids with externalized VP1\/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol. 2006;80:11040\u201354.","journal-title":"J Virol"},{"key":"561_CR145","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/mt.2010.250","volume":"19","author":"LE Mays","year":"2011","unstructured":"Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther. 2011;19:16\u201327.","journal-title":"Mol Ther"},{"key":"561_CR146","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381\u201390.","journal-title":"J Infect Dis"},{"key":"561_CR147","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"V Louis Jeune","year":"2013","unstructured":"Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59\u201367.","journal-title":"Hum Gene Ther Methods"},{"key":"561_CR148","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/gt.2015.109","volume":"23","author":"B Greenberg","year":"2016","unstructured":"Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Pogoda JM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther. 2016;23:313\u20139.","journal-title":"Gene Ther"},{"key":"561_CR149","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/hum.2023.117","volume":"35","author":"C Wei","year":"2024","unstructured":"Wei C, Li D, Zhang M, Zhao Y, Liu Y, Fan Y, et al. Prevalence of adeno-associated virus-9-neutralizing antibody in Chinese patients with Duchenne muscular dystrophy. Hum Gene Ther. 2024;35:26\u201335.","journal-title":"Hum Gene Ther"},{"key":"561_CR150","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1089\/hum.2024.079","volume":"35","author":"X Qin","year":"2024","unstructured":"Qin X, Li H, Zhao H, Xiang K, Liu S, Lou R, et al. Prevalence of neutralizing antibodies against AAV Serotypes 2 and 9 in healthy participants from multiple centers across China and patients with DMD\/BMD. Hum Gene Ther. 2024;35:969\u201377.","journal-title":"Hum Gene Ther"},{"key":"561_CR151","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1089\/hum.2022.081","volume":"34","author":"S Verma","year":"2023","unstructured":"Verma S, Nwosu SN, Razdan R, Upadhyayula SR, Phan HC, Koroma AA, et al. Seroprevalence of adeno-associated virus neutralizing antibodies in males with Duchenne muscular dystrophy. Hum Gene Ther. 2023;34:430\u20138.","journal-title":"Hum Gene Ther"},{"key":"561_CR152","doi-asserted-by":"publisher","unstructured":"Leborgne C, Latournerie V, Boutin S, Desgue D, Qu\u00e9r\u00e9 A, Pignot E et al. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Cell Immunol 2018. https:\/\/doi.org\/10.1016\/j.cellimm.2018.03.004.","DOI":"10.1016\/j.cellimm.2018.03.004"},{"key":"561_CR153","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","volume":"14","author":"A Kruzik","year":"2019","unstructured":"Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, et al. Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev. 2019;14:126\u201333.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR154","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber T. Anti-AAV Antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol. 2021;12:658399.","journal-title":"Front Immunol"},{"key":"561_CR155","unstructured":"Genethon- Microdystrophin Gene Therapy (GNT-016-MYDF)|DMD Hub. https:\/\/dmdhub.org\/trials\/genethon-microdystrophin-gene-therapy-gnt-016-mydf\/ (accessed 14 May 2025)."},{"key":"561_CR156","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/JVI.01990-07","volume":"82","author":"AK Zaiss","year":"2008","unstructured":"Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NCW, Holers VM, et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008;82:2727\u201340.","journal-title":"J Virol"},{"key":"561_CR157","doi-asserted-by":"publisher","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D\u2019Souza P, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest 2024; 134. https:\/\/doi.org\/10.1172\/JCI173510.","DOI":"10.1172\/JCI173510"},{"key":"561_CR158","unstructured":"Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease | Rocket Pharmaceuticals, Inc. https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-announces-positive-gene-expression\/ (accessed 4 Mar 2025)."},{"key":"561_CR159","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fr\u00e9meaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6:4266\u201370.","journal-title":"Blood Adv"},{"key":"561_CR160","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatrics. 2021;231:265\u20138.","journal-title":"J Pediatrics"},{"key":"561_CR161","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"561_CR162","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","volume":"84","author":"V Ricotti","year":"2013","unstructured":"Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84:698\u2013705.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"561_CR163","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347\u201361.","journal-title":"Lancet Neurol"},{"key":"561_CR164","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku B, Sethw Hassan I, Howitt R, Webster CP, Harriss E, McBlane F, et al. A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol Ther. 2024;32:3220\u201359.","journal-title":"Mol Ther"},{"key":"561_CR165","doi-asserted-by":"publisher","first-page":"e213604","DOI":"10.1212\/WNL.0000000000213604","volume":"104","author":"M Oskoui","year":"2025","unstructured":"Oskoui M, Caller TA, Parsons JA, Servais L, Butterfield RJ, Bharadwaj J, et al. Delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy: evidence in focus. Neurology. 2025;104:e213604.","journal-title":"Neurology"},{"key":"561_CR166","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJE, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342\u20137.","journal-title":"Nat Med"},{"key":"561_CR167","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.V42.4.601.601","volume":"42","author":"R Storb","year":"1973","unstructured":"Storb R, Kolb HJ, Graham TC, Kolb H, Weiden PL, Thomas ED. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood. 1973;42:601\u20139.","journal-title":"Blood"},{"key":"561_CR168","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","volume":"15","author":"Z Wang","year":"2007","unstructured":"Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther. 2007;15:1160\u20136.","journal-title":"Mol Ther"},{"key":"561_CR169","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","volume":"89","author":"R Storb","year":"1997","unstructured":"Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-Identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048\u201354.","journal-title":"Blood"},{"key":"561_CR170","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood.V91.7.2581","volume":"91","author":"C Yu","year":"1998","unstructured":"Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood. 1998;91:2581\u20137.","journal-title":"Blood"},{"key":"561_CR171","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood.V44.1.57.57","volume":"44","author":"R Storb","year":"1974","unstructured":"Storb R, Gluckman E, Thomas ED, Buckner CD, Gift RA, Fefer A, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood. 1974;44:57\u201375.","journal-title":"Blood"},{"key":"561_CR172","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1182\/blood.V84.3.941.941","volume":"84","author":"R Storb","year":"1994","unstructured":"Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941\u20139.","journal-title":"Blood"},{"key":"561_CR173","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/mt.2011.108","volume":"19","author":"V Monteilhet","year":"2011","unstructured":"Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, Montus M-F, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011;19:2084\u201391.","journal-title":"Mol Ther"},{"key":"561_CR174","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/humc.2015.068","volume":"26","author":"M Corti","year":"2015","unstructured":"Corti M, Cleaver B, Cl\u00e9ment N, Conlon TJ, Faris KJ, Wang G, et al. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev. 2015;26:185\u201393.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"561_CR175","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/mt.2009.150","volume":"17","author":"VR Arruda","year":"2009","unstructured":"Arruda VR, Favaro P, Finn JD. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther J Am Soc Gene Ther. 2009;17:1492.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"561_CR176","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","volume":"4","author":"VM Velazquez","year":"2017","unstructured":"Velazquez VM, Meadows AS, Pineda RJ, Camboni M, McCarty DM, Fu H. Effective depletion of pre-existing Anti-AAV antibodies requires broad immune targeting. Mol Ther Methods Clin Dev. 2017;4:159\u201368.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR177","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2020.11.003","volume":"20","author":"H Hayashita-Kinoh","year":"2021","unstructured":"Hayashita-Kinoh H, Guillermo P-H, Nitahara-Kasahara Y, Kuraoka M, Okada H, Chiyo T, et al. Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment. Mol Ther Methods Clin Dev. 2021;20:133\u201341.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR178","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","volume":"24","author":"N Maheshri","year":"2006","unstructured":"Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 2006;24:198\u2013204.","journal-title":"Nat Biotechnol"},{"key":"561_CR179","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMcibr2118576","volume":"386","author":"JS Chamberlain","year":"2022","unstructured":"Chamberlain JS. A boost for muscle with gene therapy. N. Engl J Med. 2022;386:1184\u20136.","journal-title":"N. Engl J Med"},{"key":"561_CR180","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1083\/jcb.9.2.493","volume":"9","author":"A Mauro","year":"1961","unstructured":"Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493\u20135.","journal-title":"J Biophys Biochem Cytol"},{"key":"561_CR181","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1152\/physrev.00043.2011","volume":"93","author":"H Yin","year":"2013","unstructured":"Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013;93:23\u201367.","journal-title":"Physiol Rev"},{"key":"561_CR182","doi-asserted-by":"publisher","first-page":"14038","DOI":"10.1038\/mtm.2014.38","volume":"1","author":"AL Arnett","year":"2014","unstructured":"Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, et al. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev. 2014;1:14038.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR183","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407\u201311.","journal-title":"Science"},{"key":"561_CR184","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","volume":"27","author":"ME Nance","year":"2019","unstructured":"Nance ME, Shi R, Hakim CH, Wasala NB, Yue Y, Pan X, et al. AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol Ther. 2019;27:1568\u201385.","journal-title":"Mol Ther"},{"key":"561_CR185","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21:1455\u201363.","journal-title":"Nat Med"},{"key":"561_CR186","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbrc.2009.11.144","volume":"391","author":"K Yamashita","year":"2010","unstructured":"Yamashita K, Suzuki A, Satoh Y, Ide M, Amano Y, Masuda-Hirata M, et al. The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b. Biochem Biophys Res Commun. 2010;391:812\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"561_CR187","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1128\/JVI.77.6.3495-3504.2003","volume":"77","author":"BC Schnepp","year":"2003","unstructured":"Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003;77:3495\u2013504.","journal-title":"J Virol"},{"key":"561_CR188","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","volume":"113","author":"GP Niemeyer","year":"2009","unstructured":"Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113:797\u2013806.","journal-title":"Blood"},{"key":"561_CR189","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876\u201385.","journal-title":"Mol Ther"},{"key":"561_CR190","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JND-210683","volume":"8","author":"J Morgan","year":"2021","unstructured":"Morgan J, Muntoni F. Changes in myonuclear number during postnatal growth - implications for AAV Gene therapy for muscular dystrophy. J Neuromuscul Dis. 2021;8:S317\u2013S324.","journal-title":"J Neuromuscul Dis"},{"key":"561_CR191","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1073\/pnas.240335297","volume":"97","author":"B Wang","year":"2000","unstructured":"Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA. 2000;97:13714\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"561_CR192","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/mt.2008.28","volume":"16","author":"P Gregorevic","year":"2008","unstructured":"Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther. 2008;16:657\u201364.","journal-title":"Mol Ther"},{"key":"561_CR193","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/mt.2011.154","volume":"19","author":"B Bostick","year":"2011","unstructured":"Bostick B, Shin J-H, Yue Y, Duan D. AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther. 2011;19:1826\u201332.","journal-title":"Mol Ther"},{"key":"561_CR194","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.05.002","volume":"53","author":"B Bostick","year":"2012","unstructured":"Bostick B, Shin J-H, Yue Y, Wasala NB, Lai Y, Duan D. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J Mol Cell Cardiol. 2012;53:217\u201322.","journal-title":"J Mol Cell Cardiol"},{"key":"561_CR195","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/hum.2022.181","volume":"34","author":"NB Wasala","year":"2023","unstructured":"Wasala NB, Yue Y, Hu B, Shin J-H, Srivastava A, Yao G, et al. Lifelong outcomes of systemic adeno-associated virus micro-dystrophin gene therapy in a murine Duchenne muscular dystrophy model. Hum Gene Ther. 2023;34:449\u201358.","journal-title":"Hum Gene Ther"},{"key":"561_CR196","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/mt.2008.207","volume":"16","author":"Y Yue","year":"2008","unstructured":"Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN, et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther. 2008;16:1944\u201352.","journal-title":"Mol Ther"},{"key":"561_CR197","doi-asserted-by":"publisher","first-page":"e120474","DOI":"10.1172\/jci.insight.120474","volume":"3","author":"W Shao","year":"2018","unstructured":"Shao W, Earley LF, Chai Z, Chen X, Sun J, He T, et al. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. JCI Insight. 2018;3:e120474. 120474","journal-title":"JCI Insight"},{"key":"561_CR198","doi-asserted-by":"publisher","first-page":"e0203921","DOI":"10.1128\/jvi.02039-21","volume":"96","author":"A Das","year":"2022","unstructured":"Das A, Vijayan M, Walton EM, Stafford VG, Fiflis DN, Asokan A. Epigenetic silencing of recombinant adeno-associated virus genomes by NP220 and the HUSH complex. J Virol. 2022;96:e0203921.","journal-title":"J Virol"},{"key":"561_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13405-9","volume":"12","author":"A Mollard","year":"2022","unstructured":"Mollard A, Peccate C, Forand A, Chassagne J, Julien L, Meunier P, et al. Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription. Sci Rep. 2022;12:9674.","journal-title":"Sci Rep"},{"key":"561_CR200","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/mtm.2015.10","volume":"2","author":"J-B Dupont","year":"2015","unstructured":"Dupont J-B, Tournaire B, Georger C, Marolleau B, Jeanson-Leh L, Ledevin M, et al. Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev. 2015;2:15010.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"561_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70987-y","volume":"10","author":"DW Hammers","year":"2020","unstructured":"Hammers DW, Hart CC, Matheny MK, Wright LA, Armellini M, Barton ER, et al. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy. Sci Rep. 2020;10:14070.","journal-title":"Sci Rep"},{"key":"561_CR202","doi-asserted-by":"publisher","first-page":"e165869","DOI":"10.1172\/jci.insight.165869","volume":"9","author":"CC Hart","year":"2024","unstructured":"Hart CC, Lee YI, Xie J, Gao G, Lin BL, Hammers DW, et al. Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy. JCI Insight. 2024;9:e165869.","journal-title":"JCI Insight"},{"key":"561_CR203","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","author":"AAV High-dose","year":"2020","unstructured":"High-dose AAV. Gene therapy deaths. Nat Biotechnol. 2020;38:910\u2013910.","journal-title":"Nat Biotechnol"},{"key":"561_CR204","unstructured":"Philippidis A. Lysogene Confirms Child\u2019s Death in Phase II\/III Gene Therapy Trial. GEN - Genetic Engineering and Biotechnology News. 2020. https:\/\/www.genengnews.com\/news\/lysogene-confirms-childs-death-in-phase-ii-iii-gene-therapy-trial\/ (accessed 18 Feb 2025)."},{"key":"561_CR205","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. Novartis confirms deaths of two patients treated with gene therapy Zolgensma. Hum Gene Ther. 2022;33:842\u20134.","journal-title":"Hum Gene Ther"},{"key":"561_CR206","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, et al. Death after High-Dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;389:1203\u201310.","journal-title":"N Engl J Med"},{"key":"561_CR207","unstructured":"Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement \u2022 Solid Biosciences Inc. https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-announces-acquisition-aavantibio-and (accessed 10 Mar 2025)."},{"key":"561_CR208","unstructured":"Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 \u2022 Solid Biosciences Inc. https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-reports-positive-initial-clinical-data-next (accessed 14 May 2025)."},{"key":"561_CR209","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2024.2776","volume":"331","author":"L Bendicksen","year":"2024","unstructured":"Bendicksen L, Kesselheim AS, Rome BN. Spending on targeted therapies for Duchenne muscular dystrophy. JAMA. 2024;331:1151\u20133.","journal-title":"JAMA"},{"key":"561_CR210","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm.3628","volume":"20","author":"N Wein","year":"2014","unstructured":"Wein N, Vulin A, Falzarano MS, Szigyarto CA-K, Maiti B, Findlay A, et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med. 2014;20:992\u20131000.","journal-title":"Nat Med"},{"key":"561_CR211","doi-asserted-by":"publisher","unstructured":"Gushchina LV, Bradley AJ, Vetter TA, Lay JW, Rohan NL, Frair EC, et al. Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model. Mol Therapy Methods Clin Devel. 2023;31. https:\/\/doi.org\/10.1016\/j.omtm.2023.101144.","DOI":"10.1016\/j.omtm.2023.101144"},{"key":"561_CR212","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","volume":"29","author":"A Pickar-Oliver","year":"2021","unstructured":"Pickar-Oliver A, Gough V, Bohning JD, Liu S, Robinson-Hamm JN, Daniels H, et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther. 2021;29:3243\u201357.","journal-title":"Mol Ther"},{"key":"561_CR213","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","volume":"632","author":"H Tasfaout","year":"2024","unstructured":"Tasfaout H, Halbert CL, McMillen TS, Allen JM, Reyes TR, Flint GV, et al. Split intein-mediated protein trans-splicing to express large dystrophins. Nature. 2024;632:192\u2013200.","journal-title":"Nature"},{"key":"561_CR214","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1126\/science.adp8179","volume":"386","author":"SR Lindley","year":"2024","unstructured":"Lindley SR, Subbaiah KCV, Priyanka F, Poosala P, Ma Y, Jalinous L, et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science. 2024;386:762\u20137.","journal-title":"Science"},{"key":"561_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50569-6","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang C, Xiao W, Herzog RW, Han R. Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice. Nat Commun. 2024;15:6141.","journal-title":"Nat Commun"},{"key":"561_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00152-5","volume":"7","author":"JR Counsell","year":"2017","unstructured":"Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, et al. Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep. 2017;7:79.","journal-title":"Sci Rep"},{"key":"561_CR217","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0960-8966(97)00054-0","volume":"7","author":"J Huard","year":"1997","unstructured":"Huard J, Krisky D, Oligino T, Marconi P, Day CS, Watkins SC, et al. Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord. 1997;7:299\u2013313.","journal-title":"Neuromuscul Disord"},{"key":"561_CR218","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/104303404772679959","volume":"15","author":"RWR Dudley","year":"2004","unstructured":"Dudley RWR, Lu Y, Gilbert R, Matecki S, Nalbantoglu J, Petrof BJ, et al. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther. 2004;15:145\u201356.","journal-title":"Hum Gene Ther"},{"key":"561_CR219","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31:3123\u20136.","journal-title":"Mol Ther"},{"key":"561_CR220","doi-asserted-by":"publisher","first-page":"104441.615","DOI":"10.1016\/j.nmd.2024.07.624","volume":"43","author":"R Masson","year":"2024","unstructured":"Masson R, Proud C, Finkel R, Parsons J, Kuntz N, Foster R, et al. 180\u2009P Interim results from RESPOND: a study of nusinersen in children with spinal muscular atrophy (SMA) previously treated with onasemnogene abeparvovec (OA). Neuromuscul Disord. 2024;43:104441.615.","journal-title":"Neuromuscul Disord"},{"key":"561_CR221","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/acn3.52093","volume":"11","author":"SE Matesanz","year":"2024","unstructured":"Matesanz SE, Brigatti KW, Young M, Yum SW, Strauss KA. Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy. Ann Clin Transl Neurol. 2024;11:1868\u201378.","journal-title":"Ann Clin Transl Neurol"},{"key":"561_CR222","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/hmg\/ddw201","volume":"25","author":"C Peccate","year":"2016","unstructured":"Peccate C, Mollard A, Le Hir M, Julien L, McClorey G, Jarmin S, et al. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet. 2016;25:3555\u201363.","journal-title":"Hum Mol Genet"},{"key":"561_CR223","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017\u201326.","journal-title":"Lancet"},{"key":"561_CR224","unstructured":"Nationwide Children\u2019s Announces Restoration of Full-Length Dystrophin Using Dup 2 Gene Therapy Approach. Parent Project Muscular Dystrophy. 2022. https:\/\/www.parentprojectmd.org\/nationwide-childrens-hospital-announces-restoration-of-full-length-dystrophin-using-duplication-2-gene-therapy-approach\/ (accessed 28 Aug 2022)."},{"key":"561_CR225","doi-asserted-by":"publisher","unstructured":"Roberts TC. Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications. Mol Therapy Methods Clin Devel. 2023;31. https:\/\/doi.org\/10.1016\/j.omtm.2023.101160.","DOI":"10.1016\/j.omtm.2023.101160"},{"key":"561_CR226","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/jcsm.12506","volume":"11","author":"TLE van Westering","year":"2020","unstructured":"van Westering TLE, Lomonosova Y, Coenen\u2010Stass AML, Betts CA, Bhomra A, Hulsker M, et al. Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. J Cachexia, Sarcopenia Muscle. 2020;11:578\u201393.","journal-title":"J Cachexia, Sarcopenia Muscle"},{"key":"561_CR227","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtn.2022.10.010","volume":"30","author":"B Hanson","year":"2022","unstructured":"Hanson B, Stenler S, Ahlskog N, Chwalenia K, Svrzikapa N, Coenen-Stass AML, et al. Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin\/utrophin double-knockout mouse model of DMD. Mol Ther Nucleic Acids. 2022;30:379\u201397.","journal-title":"Mol Ther Nucleic Acids"},{"key":"561_CR228","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.omtn.2022.08.033","volume":"29","author":"K Chwalenia","year":"2022","unstructured":"Chwalenia K, Oieni J, Zem\u0142a J, Lekka M, Ahlskog N, Coenen-Stass AML, et al. Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties. Mol Ther Nucleic Acids. 2022;29:955\u201368.","journal-title":"Mol Ther Nucleic Acids"},{"key":"561_CR229","doi-asserted-by":"publisher","first-page":"e2206324120","DOI":"10.1073\/pnas.2206324120","volume":"120","author":"A Morin","year":"2023","unstructured":"Morin A, Stantzou A, Petrova ON, Hildyard J, Tensorer T, Matouk M, et al. Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proc Natl Acad Sci. 2023;120:e2206324120.","journal-title":"Proc Natl Acad Sci"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00561-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:06:33Z","timestamp":1760375193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00561-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":229,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00561-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJAW is an advisor and shareholder in PepGen Ltd, a biotechnology company that aims to generate exon skipping therapies for DMD. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}